Moderna: Is the Dolly Parton-backed biotech a good investment?
smh.com.au
finance
2022-05-31 19:05:00

The bull case: Moderna wowed the market when it released first-quarter earnings at the start of this month. Its $US6.1 billion ($8.1 billion) in revenues and $US3.7 billion ($5.1 billion) in earnings smashed analyst expectations, showing that global demand for vaccines is translating into cash.The business has always been focused on more than COVID-19, however, and has a strong pipeline of other messenger-RNA based vaccines and therapies. It recently committed to prioritising research for 15 new vaccines for diseases affecting low- and middle-income countries.
